|
Active substance |
Fingolimod |
|
Holder |
Novartis Pharma NV |
|
Status |
Closed |
|
Indication |
Relapsing multiple sclerosis (RMS) in for pediatric patients aged 10 to less than 18 years old of 40 kg or above. |
|
Public documents |
|
|
Informed consent (≥10-<12 years) |
|
|
Last update |
02/12/2019 |
Gilenya®
Last updated on 10/09/2024